Indivior (NASDAQ:INDV) is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine. The company is headquartered in Slough, United Kingdom, with a major operations and manufacturing hub in Richmond, Virginia. Since its inception, Indivior has sought to expand access to evidence-based treatments through ongoing clinical research and strategic collaborations.
Beyond its core opioid dependence offerings, Indivior maintains a pipeline of investigational therapies aimed at addressing alcohol use disorder and other psychiatric conditions. The company invests in clinical development programs to explore novel formulations, delivery technologies and digital health solutions intended to enhance treatment adherence and patient outcomes.
Today, Indivior markets its products across North America, Europe, Australia and other key regions, supporting healthcare professionals with educational and patient-support initiatives. Through its global footprint, the company aims to reduce barriers to care and improve long-term recovery rates for individuals affected by addiction worldwide.
